CN104093402A - Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 - Google Patents

Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 Download PDF

Info

Publication number
CN104093402A
CN104093402A CN201380006947.7A CN201380006947A CN104093402A CN 104093402 A CN104093402 A CN 104093402A CN 201380006947 A CN201380006947 A CN 201380006947A CN 104093402 A CN104093402 A CN 104093402A
Authority
CN
China
Prior art keywords
unsubstituted
compound
replace
pharmaceutically
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380006947.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·约文
M·斯奎雷斯
C·雷迪克
张勇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN104093402A publication Critical patent/CN104093402A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380006947.7A 2012-01-31 2013-01-30 Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用 Pending CN104093402A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261593047P 2012-01-31 2012-01-31
US61/593,047 2012-01-31
PCT/US2013/023781 WO2013116293A1 (en) 2012-01-31 2013-01-30 Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN104093402A true CN104093402A (zh) 2014-10-08

Family

ID=47679114

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380006947.7A Pending CN104093402A (zh) 2012-01-31 2013-01-30 Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用

Country Status (12)

Country Link
US (1) US20140378422A1 (enExample)
EP (1) EP2809312A1 (enExample)
JP (1) JP2015505562A (enExample)
KR (1) KR20140117457A (enExample)
CN (1) CN104093402A (enExample)
AU (1) AU2013215251A1 (enExample)
BR (1) BR112014017985A8 (enExample)
CA (1) CA2861377A1 (enExample)
IN (1) IN2014DN05869A (enExample)
MX (1) MX2014009303A (enExample)
RU (1) RU2014135436A (enExample)
WO (1) WO2013116293A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111787922A (zh) * 2018-01-10 2020-10-16 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
CN112912078A (zh) * 2018-09-13 2021-06-04 恒翼生物医药科技(上海)有限公司 用于治疗雌激素受体阳性乳腺癌的组合疗法

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017507964A (ja) * 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
RU2712222C2 (ru) 2015-03-25 2020-01-27 Нэшнл Кэнсер Сентер Терапевтическое средство против рака желчных протоков
NZ743651A (en) * 2015-12-09 2023-07-28 Univ Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2017104739A1 (ja) 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
KR20220110859A (ko) 2016-03-04 2022-08-09 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
MX2020009762A (es) 2018-03-19 2021-01-08 Taiho Pharmaceutical Co Ltd Composicion farmaceutica que incluye alquil sulfato de sodio.
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
EP3888643A4 (en) * 2018-11-26 2022-08-24 Taiho Pharmaceutical Co., Ltd. Therapeutic and prophylactic method for tumor treatable with endocrine therapy by combined use of fibroblast growth factor receptor inhibitor with endocrine therapy
KR20230047056A (ko) * 2020-07-31 2023-04-06 에자이 알앤드디 매니지먼트 가부시키가이샤 유방암 치료제
EP4302763A4 (en) * 2021-03-03 2024-11-27 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Combined pharmaceutical composition containing cdk4/6 inhibitor and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081445A2 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors
CN101222850A (zh) * 2005-05-13 2008-07-16 诺瓦提斯公司 治疗对药物有抗性的癌症的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (enExample) 1962-09-13
US4418068A (en) 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
GB2126576B (en) 1982-06-25 1985-06-19 Farmos Group Limited Alkane and alkene derivatives
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
WO2000009495A1 (en) 1998-08-11 2000-02-24 Novartis Ag Isoquinoline derivatives with angiogenesis inhibiting activity
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
ITTV20030095A1 (it) 2003-07-14 2005-01-15 Asolo Spa Calzatura con sottopiede composito.
WO2005047244A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
NZ563692A (en) 2005-05-23 2011-04-29 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
PL1957074T3 (pl) 2005-11-29 2014-08-29 Novartis Ag Preparaty chinolinonów
US20080206194A1 (en) * 2007-02-16 2008-08-28 Glazer Robert I Method for the treatment of breast cancer
AR070924A1 (es) 2008-03-19 2010-05-12 Novartis Ag Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
UY33472A (es) 2010-06-30 2012-01-31 Novartis Ag ?composiciones farmacéuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1hbencimidazol-2-il]-1h-quinolin-2-ona?.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006081445A2 (en) * 2005-01-27 2006-08-03 Novartis Vaccines And Diagnostics Inc. Treatment of metastasized tumors
CN101222850A (zh) * 2005-05-13 2008-07-16 诺瓦提斯公司 治疗对药物有抗性的癌症的方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DANIEL E. LOPES DEMENEZES,ET AL: "CHIR-258: A Potent Inhibitor of FLT3 Kinase in Experimental Tumor Xenograft Models of Human Acute Myelogenous Leukemia", 《CLIN CANCER RES》 *
JULIEN H. DEY, ET AL: "Targeting Fibroblast Growth Factor Receptors Blocks PI3K/AKT Signaling, Induces Apoptosis, and Impairs Mammary Tumor Outgrowth and Metastasis", 《CANCER RESEARCH》 *
NICHOLAS TURNER, ET AL.: "FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer", 《CANCER RESEARCH》 *
VICTORIA KNIGHTS, ET AL.: "De-regulated FGF receptors as therapeutic targets in cancer", 《PHARMACOLOGY & THERAPEUTICS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111787922A (zh) * 2018-01-10 2020-10-16 卫材 R&D 管理有限公司 用于治疗肝细胞癌的组合疗法
US11833119B2 (en) 2018-01-10 2023-12-05 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of hepatocellular carcinoma
CN112912078A (zh) * 2018-09-13 2021-06-04 恒翼生物医药科技(上海)有限公司 用于治疗雌激素受体阳性乳腺癌的组合疗法

Also Published As

Publication number Publication date
AU2013215251A1 (en) 2014-08-14
BR112014017985A8 (pt) 2017-07-11
WO2013116293A1 (en) 2013-08-08
CA2861377A1 (en) 2013-08-08
KR20140117457A (ko) 2014-10-07
JP2015505562A (ja) 2015-02-23
IN2014DN05869A (enExample) 2015-05-22
BR112014017985A2 (enExample) 2017-06-20
RU2014135436A (ru) 2016-03-27
MX2014009303A (es) 2014-10-14
EP2809312A1 (en) 2014-12-10
US20140378422A1 (en) 2014-12-25

Similar Documents

Publication Publication Date Title
CN104093402A (zh) Rtk抑制剂与抗雌激素的组合及其治疗癌症的应用
AU2021282467B2 (en) AR+ breast cancer treatment methods
US9421208B2 (en) Methods for the treatment of solid tumors
JP6926066B2 (ja) 癌を治療するための方法
US20130345217A1 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
US20130123272A1 (en) Organic compound for use in the treatment of liver cancer
US20140275089A1 (en) 2-Carboxamide Cycloamino Urea Derivatives in Combination with HSP90 Inhibitors for the Treatment of Proliferative Diseases
JP2015536986A (ja) 併用療法
EP1885187B1 (en) Methods for treating drug resistant cancer
US8962679B2 (en) Daidzein analogs as treatment for cancer
CN104661681B (zh) 包含磷脂酰肌醇3-激酶抑制剂和芳香酶抑制剂的药物组合
TW201420102A (zh) 組合療法
KR20150064857A (ko) 혈관 신생작용 관련 질환 치료를 위한 HIF-1α 저해 화합물
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
BR112018076001B1 (pt) Uso de rad140 (composto iii) para tratamento de câncer de mama ar+/ er+"
CA3072389A1 (en) Selective beta2-adrenergic receptor antagonist for treating von hippel-lindau
HK1110477B (en) Methods for treating drug resistant cancer
NZ617243B2 (en) Combinations of akt and mek inhibitor compounds, and methods of use
NZ617243A (en) Combinations of akt and mek inhibitor compounds, and methods of use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141008